Payment overview · 2025
General Payments
$460.93
26 reported records · 8 companies
Healthcare provider profile · identity verified
James D Gentry, MD
Allopathic & Osteopathic Physicians|Family Medicine · LOUISVILLE, MS · NPI 1568756252
Verified facts
What the public records show
CMS Open Payments records show James D Gentry, MD received $460.93 in general payments during 2025 across 26 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 376 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 293 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $136.04 | 29.5% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $132.62 | 28.8% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $112.57 | 24.4% | 7 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $18.15 | 3.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.90 | 3.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.89 | 3.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.12 | 3.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.64 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $460.93 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $132.62 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $121.06 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $112.57 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $112.57 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $95.63 | 5 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 293 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 376 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 249 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
376 | 68 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
196 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
249 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
293 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1230 | 222 |
| Amlodipine Besylate | Amlodipine Besylate | 1021 | 220 |
| Levothyroxine Sodium | Levothyroxine Sodium | 758 | 93 |
| Gabapentin | Gabapentin | 732 | 143 |
| Potassium Chloride | Potassium Chloride | 694 | 125 |
| Losartan Potassium | Losartan Potassium | 693 | 150 |
| Furosemide | Furosemide | 644 | 110 |
| Sertraline Hcl | Sertraline Hcl | 644 | 97 |
| Omeprazole | Omeprazole | 591 | 115 |
| Metoprolol Succinate | Metoprolol Succinate | 541 | 104 |
| Hydrochlorothiazide | Hydrochlorothiazide | 522 | 106 |
| Memantine Hcl | Memantine Hcl | 512 | 84 |
| Trazodone Hcl | Trazodone Hcl | 493 | 78 |
| Famotidine | Famotidine | 481 | 87 |
| Donepezil Hcl | Donepezil Hcl | 479 | 73 |
| Prednisone | Prednisone | 444 | 255 |
| Tamsulosin Hcl | Tamsulosin Hcl | 434 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 422 | 81 |
| Farxiga | Dapagliflozin Propanediol | 376 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 357 | 63 |
| Metformin Hcl | Metformin Hcl | 355 | 75 |
| Carvedilol | Carvedilol | 331 | 59 |
| Lisinopril | Lisinopril | 317 | 81 |
| Eliquis | Apixaban | 293 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 277 | 108 |
| Duloxetine Hcl | Duloxetine Hcl | 270 | 33 |
| Montelukast Sodium | Montelukast Sodium | 260 | 54 |
| Meloxicam | Meloxicam | 251 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 250 | 50 |
| Ozempic | Semaglutide | 249 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 246 | 67 |
| Escitalopram Oxalate | Escitalopram Oxalate | 219 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 216 | 60 |
| Jardiance | Empagliflozin | 196 | 24 |
| Olanzapine | Olanzapine | 186 | 18 |
| Metformin Hcl Er | Metformin Hcl | 184 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 182 | 68 |
| Allopurinol | Allopurinol | 170 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 159 | 76 |
| Atenolol | Atenolol | 155 | 31 |
| Mirtazapine | Mirtazapine | 152 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 145 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 145 | 33 |
| Januvia | Sitagliptin Phosphate | 144 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 23 |
| Spironolactone | Spironolactone | 143 | 37 |
| Midodrine Hcl | Midodrine Hcl | 141 | 14 |
| Xarelto | Rivaroxaban | 140 | 22 |
| Sucralfate | Sucralfate | 136 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 129 | 15 |
| Temazepam | Temazepam | 123 | 22 |
| Alprazolam | Alprazolam | 120 | 22 |
| Buspirone Hcl | Buspirone Hcl | 117 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 117 | 48 |
| Simvastatin | Simvastatin | 117 | 26 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 117 | 88 |
| Levetiracetam | Levetiracetam | 116 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 116 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 107 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 102 | 22 |
| Aripiprazole | Aripiprazole | 101 | 15 |
| Finasteride | Finasteride | 101 | 17 |
| Lorazepam | Lorazepam | 99 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 99 | 20 |
| Ezetimibe | Ezetimibe | 92 | 23 |
| Warfarin Sodium | Warfarin Sodium | 91 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 13 |
| Azithromycin | Azithromycin | 87 | 72 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 87 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 87 | 45 |
| Tramadol Hcl | Tramadol Hcl | 81 | 27 |
| Latanoprost | Latanoprost | 76 | 16 |
| Tradjenta | Linagliptin | 76 | suppressed |
| Fluconazole | Fluconazole | 75 | 47 |
| Bupropion Xl | Bupropion Hcl | 73 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 71 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 70 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 11 |
| Propranolol Hcl | Propranolol Hcl | 69 | 13 |
| Nystatin | Nystatin | 68 | 40 |
| Clonazepam | Clonazepam | 67 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 19 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 65 | 15 |
| Cefdinir | Cefdinir | 63 | 49 |
| Ondansetron Odt | Ondansetron | 63 | 32 |
| Pregabalin | Pregabalin | 63 | 14 |
| Ranolazine Er | Ranolazine | 60 | suppressed |
| Levofloxacin | Levofloxacin | 59 | 44 |
| Tresiba Flextouch U-100 | Insulin Degludec | 59 | 14 |
| Baclofen | Baclofen | 58 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 57 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 56 | suppressed |
| Glyburide | Glyburide | 55 | 20 |
| Sevelamer Carbonate | Sevelamer Carbonate | 54 | suppressed |
| Cephalexin | Cephalexin | 53 | 47 |
| Entresto | Sacubitril/Valsartan | 53 | suppressed |
| Hydrocortisone | Hydrocortisone | 53 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 52 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 51 | 12 |
| Cholestyramine | Cholestyramine (With Sugar) | 51 | 26 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 51 | suppressed |
| Lactulose | Lactulose | 50 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 13 |
| Estradiol | Estradiol | 48 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 46 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 46 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 44 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 43 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 26 |
| Risperidone | Risperidone | 42 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 41 | suppressed |
| Haloperidol | Haloperidol | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 39 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Celecoxib | Celecoxib | 38 | suppressed |
| Gemtesa | Vibegron | 38 | suppressed |
| Torsemide | Torsemide | 38 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 38 | 14 |
| Dutasteride | Dutasteride | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 36 | suppressed |
| Cilostazol | Cilostazol | 36 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 35 | suppressed |
| Scopolamine | Scopolamine | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 31 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 17 |
| Lithium Carbonate | Lithium Carbonate | 31 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 20 |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Metolazone | Metolazone | 30 | suppressed |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 21 |
| Clonidine | Clonidine | 28 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 28 | 13 |
| Glipizide | Glipizide | 28 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 28 | suppressed |
| Cyclosporine | Cyclosporine | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 26 | 18 |
| Fiasp | Insulin Aspart (Niacinamide) | 26 | suppressed |
| Folic Acid | Folic Acid | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Novolin R | Insulin Regular, Human | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Perphenazine | Perphenazine | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 11 |
| Tresiba | Insulin Degludec | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 18 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Travoprost | Travoprost | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Bethanechol Chloride | Bethanechol Chloride | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 15 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 13 | 11 |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Probenecid | Probenecid | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $460.93 · 26 records | AstraZeneca Pharmaceuticals LP | BREZTRI, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, Kerecis GraftGuide, Kerecis SurgiClose, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, The Cologuard Plus Collection Kit, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error